Clinical Trials Logo

Thrombocytopenia; Drugs clinical trials

View clinical trials related to Thrombocytopenia; Drugs.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05944445 Recruiting - Clinical trials for Thrombocytopenia; Drugs

The Incidence of Linezolid-induced Thrombocytopenia (LIT) in Critically Ill Patients, the Risk Factors for LIT

Start date: July 13, 2023
Phase:
Study type: Observational

- To identify the incidence of LIT among critically ill patients, as limited studies have only addressed this population. - To evaluate the impact of several factors on the incidence of LIT, the time to onset of LIT, and the time to recovery of platelets. - To study the effect of concurrent medications (enoxaparin, unfractinated heparin, piperacillin, carbapenems, tigecycline, fluconazole or voriconazole, digoxin, amiodarone, acetaminophen, tirofiban, statins, and antiepileptics) frequently used in critically ill patients on the incidence of LIT. - To investigate the impact of possible medications with an antioxidant effect on the prevention of LIT. - To assess the impact of LIT on composite end point (mortality, bleeding, and length of stay)

NCT ID: NCT04915287 Recruiting - Clinical trials for Chronic Liver Disease

Efficacy of Avatrombopag in Thrombocytopenic Patients With Chronic Liver Disease Undergoing an Elective Procedure

Start date: June 6, 2021
Phase: Phase 4
Study type: Interventional

In this study, investigators aimed to evaluate the efficacy of Avatrombopag in thrombocytopenic patients with chronic liver disease undergoing an elective invasive procedure through a prospective, non-randomized controlled, multicenter clinical trial. The patients were non-randomly assigned to the Avatrombopag group (119 patients) and the conventional treatment group (357 patients). The primary endpoint was the proportion of patients not requiring prophylactic platelet transfusion or rescue therapy due to bleeding from grouping up to 10 days post-procedure. Second endpoints included the proportion of patients achieving a platelet count of ≥50x10^9/L and the mean change in platelet count from baseline at the time before the procedure, the proportion of patients requiring platelet transfusion and the mean platelet transfusion units per capita, the incidence of bleeding events (WHO≥2 and requiring rescue therapy), the imaging evaluations of bleeding events, the incidence of adverse events, the changes in life quality between two groups before and after treatment, and the pharmacoeconomic index of two groups. Note: According to the results of interim statistical analysis (200-300 cases), it is up to the sponsor to decide whether to terminate the study in advance or increase the number of included cases at a later stage.